306935-26-2 Usage
Uses
Used in Medicinal Chemistry:
8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL is used as a chemical intermediate for the development of new pharmaceuticals, leveraging its unique structure and potential biological activity to target specific therapeutic areas.
Used in Pharmaceutical Research:
In pharmaceutical research, 8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL serves as a key compound for exploring its pharmacological properties, which may include interactions with biological targets and potential therapeutic effects.
Used in Organic Synthesis:
8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL is utilized as a building block in organic synthesis, particularly for the creation of fluorinated organic compounds. Its fluorinated groups impart specific properties that are valuable in various chemical and material applications.
Used in Fluorine Chemistry:
In the field of fluorine chemistry, 8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL is employed for the synthesis of complex molecules that incorporate fluorine atoms, which can enhance the reactivity, stability, and selectivity of the resulting compounds.
Used in Drug Design:
8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL is used in drug design to create novel molecules with improved pharmacokinetic and pharmacodynamic profiles, taking advantage of its unique structural features and the beneficial effects of fluorination.
Used in Biochemical Research:
In biochemical research, 8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL may be used to study its interactions with enzymes, receptors, or other biomolecules, providing insights into its potential as a therapeutic agent or a tool for understanding biological processes.
Used in Chemical Biology:
8-(TRIFLUOROMETHOXY)-2-(TRIFLUOROMETHYL)QUINOLIN-4-OL is applied in chemical biology to investigate its effects on biological systems, including its potential to modulate cellular pathways or to serve as a probe for studying the mechanisms of action of related compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 306935-26-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,6,9,3 and 5 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 306935-26:
(8*3)+(7*0)+(6*6)+(5*9)+(4*3)+(3*5)+(2*2)+(1*6)=142
142 % 10 = 2
So 306935-26-2 is a valid CAS Registry Number.
306935-26-2Relevant academic research and scientific papers
ANTIBIOTIC COMPOSITIONS
-
Page/Page column 0139; 0140, (2017/09/02)
The present disclosure relates to compounds having antimicrobial activity, compositions comprising said compounds in combination with β-lactam antibiotics, and methods of using the compounds and compositions.
Structure-Activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating mycobacterium tuberculosis
Lilienkampf, Annamaria,Jialin, Mao,Baojie, Wan,Yuehong, Wang,Franzblau, Scott G.,Kozikowski, Alan P.
supporting information; experimental part, p. 2109 - 2118 (2009/12/31)
Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDRTB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 μM, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 μM concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.
THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF
-
Page 41-42, (2010/02/07)
A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.
